Lincoln Pharmaceuticals logo

LINCOLN - Lincoln Pharmaceuticals Share Price

₹253.35 13.6  5.7%

Last Trade - 25/09/20

Small Cap
Market Cap £53.8m
Enterprise Value £49.1m
Revenue £41.8m
Position in Universe 907th / 3012
Unlock LINCOLN Revenue
Relative Strength (%)
1m +10.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2,661 4,002 3,653 3,616 3,662 3,865 4,213 4,676 +7.8%
+39.7 +55.6 +9.5 +10.0 +41.3 +5.2 +9.72 +11.8
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Lincoln Pharmaceuticals Ltd revenues increased 7% to RS1.04B. Net income increased 20% to RS152.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Employee Benefits Expenses decrease of 15% to RS129.2M (expense), Other Expenses decrease of 8% to RS177.1M (expense), Other Income increase of 39% to RS18M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for LINCOLN
Graphical History


LINCOLN Revenue Unlock LINCOLN Revenue

Net Income

LINCOLN Net Income Unlock LINCOLN Revenue

Normalised EPS

LINCOLN Normalised EPS Unlock LINCOLN Revenue

PE Ratio Range

LINCOLN PE Ratio Range Unlock LINCOLN Revenue

Dividend Yield Range

LINCOLN Dividend Yield Range Unlock LINCOLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LINCOLN EPS Forecasts Unlock LINCOLN Revenue
Profile Summary

Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products. The Company operates through the Pharmaceuticals Products segment. The Company offers products, such as tablets, capsules, liquid injection, cream in tubes, dry power injection, liquid in bott, liquid injection and pharma products. It has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. Its geographical segments include Domestic Sales and Export Sales. Its products include Tinnex, which is a medication for treating cochlear synaptic tinnitus; Pa 12 Proglet, which is a 1000 milligram programmed released paracetamol that is developed to offer control of pain and fever, and ARH 1, which is an anti-malarial drug that is formulated utilizing technology known as dose optimization technology.

Last Annual March 31st, 2020
Last Interim June 30th, 2020
Incorporated January 20, 1995
Public Since February 8, 1996
No. of Shareholders: n/a
No. of Employees: 1,245
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 20,000,000
Free Float (0.0%)
Eligible for
LINCOLN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LINCOLN
Upcoming Events for LINCOLN
Frequently Asked Questions for Lincoln Pharmaceuticals
What is the Lincoln Pharmaceuticals share price?

As of 25/09/20, shares in Lincoln Pharmaceuticals are trading at ₹253.35, giving the company a market capitalisation of £53.8m. This share price information is delayed by 15 minutes.

How has the Lincoln Pharmaceuticals share price performed this year?

Shares in Lincoln Pharmaceuticals are currently trading at ₹253.35 and the price has moved by 53.41% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lincoln Pharmaceuticals price has moved by 64.44% over the past year.

What are the analyst and broker recommendations for Lincoln Pharmaceuticals?

Of the analysts with advisory recommendations for Lincoln Pharmaceuticals, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Lincoln Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Lincoln Pharmaceuticals next release its financial results?

Lincoln Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Lincoln Pharmaceuticals dividend yield?

The Lincoln Pharmaceuticals dividend yield is 0.59% based on the trailing twelve month period.

Does Lincoln Pharmaceuticals pay a dividend?

Last year, Lincoln Pharmaceuticals paid a total dividend of 1.5, and it currently has a trailing dividend yield of 0.59%. Looking ahead, Lincoln Pharmaceuticals has not announced an ex-dividend date yet.

When does Lincoln Pharmaceuticals next pay dividends?

Lincoln Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on Lincoln Pharmaceuticals shares is currently 0.59%.

How do I buy Lincoln Pharmaceuticals shares?

To buy shares in Lincoln Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lincoln Pharmaceuticals?

Shares in Lincoln Pharmaceuticals are currently trading at ₹253.35, giving the company a market capitalisation of £53.8m.

Where are Lincoln Pharmaceuticals shares listed? Where are Lincoln Pharmaceuticals shares listed?

Here are the trading details for Lincoln Pharmaceuticals:

Country of listing: India
Exchange: NSI
Ticker Symbol: LINCOLN
What kind of share is Lincoln Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Lincoln Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lincoln Pharmaceuticals share price forecast 2020?

We were not able to load any forecast data for Lincoln Pharmaceuticals.

How can I tell whether the Lincoln Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lincoln Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 65.16%. At the current price of ₹253.35, shares in Lincoln Pharmaceuticals are trading at 40.2% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lincoln Pharmaceuticals PE Ratio?

The Lincoln Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 9.38. The shares are currently trading at ₹253.35.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Lincoln Pharmaceuticals?

Lincoln Pharmaceuticals's management team is headed by:

Kishor Shah - NEC
Mahendrabhai Patel - MDR
Rajnikant Patel - MDR
Hasmukhbhai Patel - EDR
Arvindbhai Patel - CCO
Ishwarlal Patel - NID
Munjal Patel - FID
Ashish Patel - DRC
Meha Patel - IND
Saurin Parikh - NID
Niren Desai - CCO
Who are the major shareholders of Lincoln Pharmaceuticals?

Here are the top five shareholders of Lincoln Pharmaceuticals based on the size of their shareholding:

Digital Biotech Pvt. Ltd. Corporation
Percentage owned: 7% (1.40m shares)
Patel (Munjal M) Individual Investor
Percentage owned: 4.08% (816k shares)
Patel (Rajnibhai G) Individual Investor
Percentage owned: 3.63% (725k shares)
Patel (Rajnikant G.) Individual Investor
Percentage owned: 3.63% (725k shares)
Paru Securities Pvt. Ltd. Corporation
Percentage owned: 2.72% (544k shares)
Similar to LINCOLN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.